GlobeNewswire

Impinj Introduces Speedway® R120 RAIN RFID Reader

Dela

 

Speedway portfolio delivers industry-leading performance and enterprise-grade reliability for retail, healthcare, logistics, and manufacturing industries

SEATTLE, June 21, 2017 (GLOBE NEWSWIRE) -- Impinj (PI), a leading provider of RAIN RFID solutions, today introduced the Impinj Speedway R120 one-port, enterprise-grade fixed reader that connects RAIN RFID-enabled items to the Internet. The Speedway reader portfolio now includes three models to support one, two, or four antennas with expansion up to 32 antennas. Speedway readers deliver industry-leading performance with proven enterprise-grade reliability, and enable users to right-size their reader selection for applications in retail, healthcare, logistics, and manufacturing.

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/93d26362-565c-478a-b87b-3e11f314e335

http://www.globenewswire.com/NewsRoom/AttachmentNg/67a2da82-1a6a-4e1c-949b-29f8c51b7fb6

Speedway R120 readers provide item-level visibility for use cases including smart fitting rooms, interactive product displays, and inventory management. With read rates up to 200 items per second, Speedway R120 readers are optimized for single read zones, with expandability to eight read zones. Available now, the Speedway R120 reader comes standard with one antenna port and can be upgraded to eight antenna ports with purchase of the Impinj R120 Port Pack which includes an Impinj antenna hub and GPIO adapter.

"Our customers have asked for a one-port reader that delivers Speedway's proven performance and reliability," said John Frederiksen, Impinj senior director of product management. "The Speedway R120 reader extends the value of the Speedway family, allowing businesses to choose the model that best meets their needs, while also providing a portfolio that easily scales to enable additional use cases as business needs change."

The Speedway portfolio is part of the Impinj platform which includes RAIN RFID endpoints, connectivity, and software. The Impinj platform wirelessly delivers Item Intelligence(TM)-an item's identity, location, and authenticity-to business and consumer applications, helping businesses improve efficiencies, increase sales, and delight customers. Organizations around the world use the Impinj platform to connect items to applications, enabling the Internet of Things.

With application development tools and hardware accessories that are common across the Speedway portfolio, users can accelerate solution development and scale deployments as business needs change. For more information about the Speedway R120 reader and Impinj connectivity products, visit: www.impinj.com/platform/connectivity.

About Impinj
Impinj (NASDAQ:PI) is a leading provider of RAIN RFID solutions. The Impinj Platform connects billions of everyday items such as apparel, medical supplies, automobile parts, drivers' licenses, food and luggage to applications such as inventory management, patient safety, asset tracking and item authentication, delivering real-time information to businesses about items they create, manage, transport and sell. The Impinj Platform wirelessly delivers information about these items' unique identity, location and authenticity, or Item Intelligence(TM), to the digital world, which Impinj believes is the essence of the Internet of Things. For more information visit www.impinj.com.

Media Relations
Jill West
Director, Marketing Communications
jwest@impinj.com 
+1-206-834-1110
 
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Impinj, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum